Local control after palliative external beam radiotherapy for bone metastases in patients with favorable prognosis

被引:3
作者
Makita, Kenji [1 ,2 ,3 ]
Hamamoto, Yasushi [2 ]
Kanzaki, Hiromitsu [2 ]
Kataoka, Masaaki [3 ]
Yamamoto, Shuhei [3 ]
Nagasaki, Kei [2 ]
Ishikawa, Hirofumi [1 ]
Takata, Noriko [1 ]
Tsuruoka, Shintaro [1 ]
Uwatsu, Kotaro [1 ]
Kido, Teruhito [1 ]
机构
[1] Ehime Univ, Dept Radiol, Grad Sch Med, Toon, Ehime 7910295, Japan
[2] Natl Hosp Org, Dept Radiat Oncol, Shikoku Canc Ctr, Matsuyama, Ehime 7910280, Japan
[3] Saiseikai Imabari Hosp, Dept Radiol, Imabari, Ehime 7991592, Japan
关键词
bone metastasis; local control; fractionated moderate-dose palliative radiotherapy; individualized radiotherapy; RADIATION-THERAPY; PREOPERATIVE EVALUATION; SCORING SYSTEM; SPINE; RADIOSURGERY; FRACTIONATION; UPDATE;
D O I
10.3892/mco.2022.2585
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Advancement in systemic therapy has increased the importance of local control (LC) of bone metastatic sites treated with radiotherapy in intermediate-term survivors (surviving >= 1 year). To establish individualized radiotherapy for bone metastases, factors affecting LC of bone metastases treated with traditional fractionated moderate dose palliative radiotherapy (FMRT) in intermediate-term survivors were evaluated. Between January 2010 and December 2019, 317 lesions in 240 patients treated with FMRT for bone metastases surviving for at least 1 year and followed-up with CT for at least 6 months were reviewed retrospectively. The median survival and radiographic follow-up times were 24 months (range, 12-123 months) and 20 months (range, 1-119 months), respectively. The median FMRT dose [biologically effective dose (BED)10] was 39.0 Gy (range, 28.0-71.7 Gy). Multivariate analysis revealed that age (>= 70 years), non-vertebral bone metastasis, bone metastasis from moderate and unfavorable primary tumor sites (esophageal, colorectal, hepatobiliary/pancreatic, kidney/ureter and sarcoma/melanoma cancers), and no administration of post-FMRT bone-modifying agents (BMAs) were unfavorable factors for LC of bone metastasis. The 2-year LC rates for FMRT doses (BED10) <= 39.0 Gy and >39.0 Gy were 90 and 87%, respectively. The 2-year LC rates of patients administered and not administered post-FMRT antineoplastic agents (ATs) were 91 and 78%, respectively. The sites of bone metastasis and primary tumors, and post-FMRT BMAs were factors associated with LC of bone metastasis in long-term survivors. However, a FMRT dose (BED10) >= 39.0 Gy and post-FMRT ATs were not significant factors.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] External-beamradiotherapy for pain control in patients with bone metastases
    Holzhaeuser, E.
    van Oorschot, B.
    Rades, D.
    ONKOLOGE, 2018, 24 (11): : 902 - 909
  • [32] Myeloma appearance after local external beam radiotherapy jet: Is it a new entity?
    Maalej, M.
    Belaid, A.
    Laabidi, M.
    Ben Romdhane, N.
    Kochbati, L.
    CANCER RADIOTHERAPIE, 2013, 17 (07): : 668 - 670
  • [33] Rapid palliative radiotherapy unit: multidisciplinary management of bone metastases
    Donato, V.
    Cianciulli, M.
    Crescenzi, M.
    Monaco, A.
    Caruso, C.
    Morrone, A.
    RADIOLOGIA MEDICA, 2012, 117 (06): : 1071 - 1078
  • [34] Stability of spinal bone metastases and survival analysis in renal cancer after radiotherapy
    Schlampp, Ingmar
    Lang, Helge
    Foerster, Robert
    Wolf, Robert
    Bostel, Tilman
    Bruckner, Thomas
    Debus, Juergen
    Rief, Harald
    TUMORI, 2015, 101 (06) : 614 - 620
  • [35] Should dexamethasone be standard in the prophylaxis of pain flare after palliative radiotherapy for bone metastases?-a debate
    Niglas, Mark
    Raman, Srinivas
    Rodin, Danielle
    Detsky, Jay
    DeAngelis, Carlo
    Soliman, Hany
    Chow, Edward
    Tsao, May N.
    ANNALS OF PALLIATIVE MEDICINE, 2018, 7 (02) : 279 - 283
  • [36] Stereotactic radiotherapy using the CyberKnife is effective for local control of bone metastases from differentiated thyroid cancer
    Ishigaki, Takayuki
    Uruno, Takashi
    Sugino, Kiminori
    Masaki, Chie
    Akaishi, Junko
    Hames, Kiyomi Y.
    Suzuki, Akifumi
    Tomoda, Chisato
    Matsuzu, Kenichi
    Ohkuwa, Keiko
    Kitagawa, Wataru
    Nagahama, Mitsuji
    Miyazaki, Shinichiro
    Ito, Koichi
    JOURNAL OF RADIATION RESEARCH, 2019, 60 (06) : 831 - 836
  • [37] Stereotactic body radiotherapy as a boost after external beam radiotherapy for high-risk prostate cancer patients
    Turna, Menekse
    Akboru, Halil
    Ermis, Ekin
    Oskeroglu, Sedenay
    Dincer, Selvi
    Altin, Suleyman
    INDIAN JOURNAL OF CANCER, 2021, 58 (04) : 518 - 524
  • [38] Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection
    Bilger, Angelika
    Bretzinger, Eva
    Fennell, Jamina
    Nieder, Carsten
    Lorenz, Hannah
    Oehlke, Oliver
    Grosu, Anca-Ligia
    Specht, Hanno M.
    Combs, Stephanie E.
    CANCER MEDICINE, 2018, 7 (06): : 2350 - 2359
  • [39] Early response assessment of palliative conventional radiotherapy for painful uncomplicated vertebral bone metastases
    Nakata, Eiji
    Sugihara, Shinsuke
    Kataoka, Masaaki
    Yamashita, Natsumi
    Furumatsu, Takayuki
    Takigawa, Tomoyuki
    Tetsunaga, Tomoko
    Ozaki, Toshifumi
    JOURNAL OF ORTHOPAEDIC SCIENCE, 2018, 23 (06) : 912 - 917
  • [40] Fractionated stereotactic radiotherapy for local control of resected brain metastases
    Traylor, Jeffrey I.
    Habib, Ahmed
    Patel, Rajan
    Muir, Matthew
    Gadot, Ron
    Briere, Tina
    Yeboa, Debra N.
    Li, Jing
    Rao, Ganesh
    JOURNAL OF NEURO-ONCOLOGY, 2019, 144 (02) : 343 - 350